CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC
Ontology highlight
ABSTRACT: The objective is to compare the efficacy and safety of CAPOXIRI+BEV therapy versus FOLFOXIRI+BEV therapy as first-line therapy in patients with metastatic colorectal cancer (mCRC).
DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms
PROVIDER: 2316883 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA